Table of Contents
ISRN Immunology
Volume 2014, Article ID 718393, 5 pages
Research Article

Comparative Analysis of the Informative Value of Radioimmunoassay and Laser Correlation Spectroscopy in Myasthenia Gravis

1Institute of General Pathology and Pathophysiology RAMS, Baltiyskaya Street, No. 8, Moscow 125315, Russia
2Moscow City Health Department, Moscow Myasthenia Center, SFHI Municipal Clinical Hospital No. 51, Alyabieva, No. 7/33, Moscow 121309, Russia

Received 19 January 2014; Accepted 19 February 2014; Published 12 March 2014

Academic Editors: M. Bakhiet and A. A. Manfredi

Copyright © 2014 Irina Alchinova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The objective of this study was to compare informative value of traditional approach (anti-AChR antibody radioimmunoassay) and evaluation of metabolic shifts by laser correlation spectroscopy in myasthenia gravis. The method based on changes in spectral characteristics of laser radiation caused by scattering in a disperse system yields a histogram reflecting particle contribution into light scatter as a function of particle radius in nanometers. The spectrum of anti-AChR-positive serum is characterized by appreciably increased contribution of particles with a radius 4.6–6.2 nm. Binding of serum components with solubilized AChR confirms that this peak is determined by elevated concentration of antibodies to this receptor. The search for the relationship between the disease severity and the distribution pattern of subfraction serum components revealed three informative zones: 6–15, 27–67, and 127–223 nm. In patients without disturbances of vital functions, the contribution of the first zone particles into light scatter increases and that of the third zone particles decreases. Considerable differences attaining the level of statistical significance in zones 4–6 and 20 nm were revealed in the spectra of serum from patients with myasthenia gravis of the same severity with and without thymoma. This opens prospects for dynamic monitoring of the efficiency of therapy.